Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• From Tiotropium to Dual Bronchodilation in COPD Management

  For decades, long-acting muscarinic antagonists such as tiotropium formed the backbone of maintenance therapy for chronic obstructive pulmonary disease. Australian guidelines, including the COPD-X plan endorsed by Lung Foundation Australia and the Thoracic Society of Australia and New Zealand, have long positioned LAMAs as a sensible starting point for patients with persistent symptoms. Yet the past decade has reshaped how clinicians think about initial and subsequent pharmacological choices, with dual bronchodilation now occupying a central place in step-up strategies.

  This shift matters for general practitioners, respiratory physicians, and pharmacists across Sydney, Melbourne, Brisbane, and regional centres where COPD remains a leading cause of admission. The following sections review why and when to move beyond tiotropium monotherapy, what the evidence shows for LAMA/LABA combinations, and how Australian prescribers can approach reimbursement through the Pharmaceutical Benefits Scheme.

  When single-agent bronchodilation reaches its ceiling

  Patients who begin tiotropium often experience meaningful improvements in dyspnoea and exacerbation frequency during the first months of therapy. Over time, however, some continue to report daily activity limitation, nocturnal symptoms, or persistent cough despite good inhaler technique. These clinical patterns suggest that maximal bronchodilation has not yet been achieved with a single mechanism.

  Mechanistically, LAMAs and LABAs target different pathways. Anticholinergics reduce resting cholinergic tone and limit mucus hypersecretion, while beta-2 agonists relax airway smooth muscle through a separate receptor pathway. Combining the two produces greater and more sustained bronchodilation than either class alone, which translates into measurable gains in lung function and symptom scores such as the mMRC and CAT.

  The continuing role of tiotropium

  Tiotropium is not being discarded. For many patients with mild-to-moderate disease and infrequent exacerbations, it remains an appropriate first step. Hand-held familiarity with the device, a well-established safety profile, and convenient once-daily dosing support adherence, particularly in older adults living in remote parts of Queensland or Western Australia where follow-up visits may be spaced further apart.

  The key is to view tiotropium as a foundation rather than a destination. When symptom control plateaus or exacerbations persist, escalation should be considered promptly, since each severe flare is associated with accelerated lung-function decline and increased cardiovascular risk.

  Clinical evidence behind LAMA/LABA combinations

  Multiple randomised trials have compared tiotropium alone with fixed-dose LAMA/LABA combinations such as tiotropium/olodaterol, aclidinium/formoterol, and glycopyrronium/indacaterol. Across studies, dual therapy consistently produced larger FEV1 improvements of 60 to 120 mL and reduced the rate of moderate-to-severe exacerbations by roughly 15 to 20 percent compared with tiotropium monotherapy.

  Outcome measure	Tiotropium monotherapy	LAMA/LABA dual bronchodilation
  Mean FEV1 improvement	100–140 mL above baseline	180–260 mL above baseline
  Moderate-to-severe exacerbations	Baseline reference	15–20% lower risk
  Dyspnoea score (TDI)	+1.0 to +1.5 units	+1.5 to +2.5 units
  Inhaler burden	One device, once daily	One device, once daily in modern fixed-dose options
  Common adverse events	Dry mouth, constipation	Dry mouth, cough, mild tachycardia

  The table highlights not only efficacy gains but also a comparable safety profile, which has encouraged clinicians across Australian tertiary centres and community settings to broaden the use of dual therapy.

  Patient profiles that benefit from escalation

  Indicators that a patient may be ready to move beyond tiotropium include:

  • Persistent CAT score above 10 despite three to six months of optimised monotherapy
  • One or more moderate exacerbations requiring antibiotics or hospital attendance in the past year
  • Morning symptoms that interrupt everyday activities such as walking the dog or climbing stairs at home
  • Self-reported limitation despite confirmed correct inhaler technique

  These signals should be weighed alongside spirometry, oxygen saturation, and comorbidities before deciding on escalation.

  Implementing the switch in everyday practice

  A successful transition starts with a careful conversation. Patients often worry that changing inhalers signals worsening disease, so framing the move as proactive optimisation helps maintain engagement. Reviewing inhaler technique with a spacer or trainer device during the consultation is particularly valuable for older patients and those whose first language is not English, a common consideration in multicultural suburbs of Melbourne and western Sydney.

  Pharmacists conducting Home Medicines Reviews under Medicare item 900 can reinforce the message, check for drug interactions, and confirm the new combination is compatible with any concurrent cardiovascular or urological agents. Scheduling a follow-up review at four to eight weeks allows clinicians to reassess symptom control, verify adherence, and titrate or adjust as needed.

  Reimbursement and access through the PBS

  Cost considerations shape prescribing decisions in Australia more than in many other countries. Several LAMA/LABA fixed-dose combinations are listed on the Pharmaceutical Benefits Scheme for patients meeting specific criteria, typically a confirmed COPD diagnosis with FEV1 below 50 percent predicted and a history of exacerbations. Tiotropium remains subsidised as a standalone option, while combinations generally require an authority script.

  Practical points for prescribers include:

  • Confirming the patient meets PBS streamlined authority criteria before writing the prescription
  • Documenting recent exacerbation history and current CAT or mMRC score in the clinical notes
  • Checking the patient's concession or safety-net status to estimate out-of-pocket costs
  • Aligning the inhaler choice with device-handling ability to support long-term adherence

  These steps reduce the risk of pharmacy callbacks, prior-authority delays, and out-of-pocket surprises that can quietly undermine adherence after the switch.

  Monitoring long-term outcomes

  Once the patient is established on dual bronchodilation, regular review remains essential. Lung function trends, exacerbation calendars, and validated questionnaires should be tracked at least annually, with more frequent checks after any hospital admission or change in clinical status. Pulmonary rehabilitation referrals, smoking-cessation support through services such as Quitline, and vaccination updates for influenza and pneumococcal disease should run alongside pharmacological therapy to deliver comprehensive care.

  The shift from tiotropium monotherapy to dual bronchodilation is rarely a single decision; it is a deliberate process grounded in evidence, patient preference, and the practical realities of Australian healthcare. When applied thoughtfully, it offers a tangible path to fewer exacerbations, better breathing, and greater capacity for the everyday activities that matter to patients and their families.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)